Geographic Atrophy Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

  • PublishedFebruary 28, 2023
Geographic Atrophy Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 23+ key pharma and biotech companies are working on 25+ pipeline drugs in the Geographic Atrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Geographic Atrophy market is expected to grow significantly in the upcoming years owing to the expected launch and readily uptake of emerging therapies along with premium price agents like gene therapies, increasing prevalent patient pool, the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and better understanding about pathophysiology, disease severity which might open the door for other companies as well.

Several major pharma and biotech giants such as Apellis Pharmaceuticals, Iveric bio, Genentech/ Roche, Ionis Pharmaceuticals/ Roche, NGM Biopharmaceuticals Stealth BioTherapeutics, Regenerative Patch Technologies, CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche, Novartis, Regenerative Patch Technologies, Luxa Biotechnology, and others are involved in developing therapies for Geographic Atrophy. 

Geographic Atrophy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Geographic Atrophy Market. 

The Geographic Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Geographic Atrophy Pipeline Analysis

Geographic Atrophy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Geographic Atrophy and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Geographic Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Geographic Atrophy Therapeutic Segment @


Geographic Atrophy Therapeutics Landscape

Several major pharma and biotech giants are developing therapies for Geographic Atrophy. Currently, IVERIC bio is leading the therapeutics market with its Geographic Atrophy drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Geographic Atrophy Therapeutics Market Include:

Alexion, AstraZeneca, Alkeus Pharmaceuticals, Annexon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma Inc, Boehringer Ingelheim, Catalyst Biosciences, Cell Cure Neurosciences LTD, Eyevensys, Gemini Therapeutics, Genentech, Gyroscope Therapeutics Limited, Hemera Biosciences LLC, Ionis Pharmaceuticals, IVERIC bio, Nanoscope Therapeutics, Inc., NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Regenerative Patch Technologies, LLC, Stealth BioTherapeutics Inc., and many others.

Geographic Atrophy Drugs Covered in the Report Include:

  • ALK-001: Alkeus Pharmaceuticals

  • CPCB-RPE1: Regenerative Patch Technologies

  • Elamipretide: Stealth BioTherapeutics

  • IONIS-FB-LRx: Ionis Pharmaceuticals/ Roche

  • NGM621: NGM Biopharmaceuticals

  • OpRegen: CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche

  • Pegcetacoplan: Apellis Pharmaceuticals

  • PPY988/GT005: Novartis

  • RG6147: Genentech

  • RO7171009; RG6147: Genentech/ Roche

  • RO7303359: Roche

  • RPESC-RPE-4W: Luxa Biotechnology

  • Zimura: Iveric bio

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Geographic Atrophy Current Treatment Patterns

4. Geographic Atrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Geographic Atrophy Late Stage Products (Phase-III)

7. Geographic Atrophy Mid-Stage Products (Phase-II)

8. Geographic Atrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Geographic Atrophy Discontinued Products

13. Geographic Atrophy Product Profiles

14. Key Companies in the Geographic Atrophy Market

15. Key Products in the Geographic Atrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Geographic Atrophy Unmet Needs

18. Geographic Atrophy Future Perspectives

19. Geographic Atrophy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Written By